Drug Trial Radar · NCT05110196
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Sep 3, 2022
Primary completion
Aug 4, 2025
Study completion Aug 4, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Drugs Controller General of India (DCGI) granted approval for Rahika® (capmatinib) film-coated tablets (150 mg and 200 mg) for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbored a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping. As a condition of approval, the DCGI required the conduct of a Phase IV clinical trial in Indian patients. As recommended by the DCGI, this Phase IV study was planned to evaluate the safety and efficacy of capmatinib in adult Indian patients with advanced or metastatic NSCLC with MET exon 14 skipping mutation-positive disease, in any line of therapy.
Conditions
- Non-Small Cell Lung Carcinoma
Interventions
Capmatinib 150 mgDrug
Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
Capmatinib 200 mgDrug
Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (Serious TEAEs)Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
- Percentage of Participants With Dose ModificationsTime frame: From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
- Dose IntensityTime frame: From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Puducherry, India
Novartis Investigative Site
Gujarat, Gujarat, India
Novartis Investigative Site
Mangalore, Karnataka, India
Novartis Investigative Site
Thalassery, Kerala, India
Novartis Investigative Site
Trivandrum, Kerala, India
Novartis Investigative Site
Bhopal, Madhya Pradesh, India
Novartis Investigative Site
Mumbai, Maharashtra, India
Novartis Investigative Site
Mumbai, Maharashtra, India
Novartis Investigative Site
Nagpur, Maharashtra, India
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Bhubaneswar, Odisha, India
Novartis Investigative Site
Hyderabad, Telangana, India
Novartis Investigative Site
Varanasi, Uttar Pradesh, India
Novartis Investigative Site
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.